Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Purchased by IFM Investors Pty Ltd

IFM Investors Pty Ltd boosted its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 2.4% during the first quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 18,677 shares of the company’s stock after buying an additional 444 shares during the quarter. IFM Investors Pty Ltd’s holdings in Neurocrine Biosciences were worth $2,576,000 as of its most recent filing with the SEC.

A number of other large investors have also recently bought and sold shares of the stock. Mather Group LLC. acquired a new stake in shares of Neurocrine Biosciences during the first quarter valued at $26,000. Headinvest LLC acquired a new stake in shares of Neurocrine Biosciences during the 3rd quarter worth about $28,000. Lindbrook Capital LLC grew its holdings in shares of Neurocrine Biosciences by 85.0% during the fourth quarter. Lindbrook Capital LLC now owns 209 shares of the company’s stock worth $28,000 after buying an additional 96 shares in the last quarter. EdgeRock Capital LLC acquired a new position in shares of Neurocrine Biosciences in the fourth quarter valued at approximately $31,000. Finally, Benjamin F. Edwards & Company Inc. purchased a new position in shares of Neurocrine Biosciences during the fourth quarter valued at approximately $33,000. Institutional investors and hedge funds own 92.59% of the company’s stock.

Insider Activity

In other Neurocrine Biosciences news, insider David W. Boyer sold 456 shares of Neurocrine Biosciences stock in a transaction on Tuesday, February 6th. The shares were sold at an average price of $141.96, for a total value of $64,733.76. Following the completion of the transaction, the insider now owns 4,894 shares of the company’s stock, valued at $694,752.24. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In other news, insider Eric Benevich sold 75,000 shares of the company’s stock in a transaction that occurred on Thursday, March 14th. The stock was sold at an average price of $139.38, for a total transaction of $10,453,500.00. Following the completion of the transaction, the insider now directly owns 40,778 shares of the company’s stock, valued at $5,683,637.64. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider David W. Boyer sold 456 shares of the firm’s stock in a transaction that occurred on Tuesday, February 6th. The stock was sold at an average price of $141.96, for a total value of $64,733.76. Following the completion of the sale, the insider now directly owns 4,894 shares in the company, valued at approximately $694,752.24. The disclosure for this sale can be found here. In the last ninety days, insiders sold 186,994 shares of company stock worth $25,806,409. 4.40% of the stock is currently owned by insiders.

Neurocrine Biosciences Trading Down 1.3 %

NASDAQ NBIX traded down $1.77 during trading hours on Friday, reaching $135.99. 717,575 shares of the company traded hands, compared to its average volume of 729,952. The company has a 50 day moving average of $136.63 and a two-hundred day moving average of $127.85. The stock has a market capitalization of $13.53 billion, a PE ratio of 56.19 and a beta of 0.25. Neurocrine Biosciences, Inc. has a 12 month low of $89.04 and a 12 month high of $148.37.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its quarterly earnings results on Wednesday, February 7th. The company reported $1.44 EPS for the quarter, topping analysts’ consensus estimates of $1.13 by $0.31. Neurocrine Biosciences had a return on equity of 12.85% and a net margin of 13.23%. The business had revenue of $515.20 million during the quarter, compared to the consensus estimate of $518.52 million. During the same period last year, the firm earned $0.88 earnings per share. The company’s revenue for the quarter was up 25.0% compared to the same quarter last year. On average, equities research analysts anticipate that Neurocrine Biosciences, Inc. will post 4.83 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts have commented on NBIX shares. HC Wainwright reiterated a “buy” rating and issued a $150.00 price target on shares of Neurocrine Biosciences in a report on Wednesday. Barclays lifted their price objective on Neurocrine Biosciences from $145.00 to $150.00 and gave the company an “overweight” rating in a research report on Tuesday, January 23rd. Wells Fargo & Company raised Neurocrine Biosciences from an “equal weight” rating to an “overweight” rating and raised their price target for the stock from $140.00 to $170.00 in a research note on Wednesday. Mizuho upped their price objective on shares of Neurocrine Biosciences from $116.00 to $140.00 and gave the company a “neutral” rating in a research note on Thursday, February 8th. Finally, Oppenheimer reiterated an “outperform” rating and set a $200.00 price objective on shares of Neurocrine Biosciences in a report on Wednesday. Six research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Neurocrine Biosciences currently has an average rating of “Moderate Buy” and a consensus price target of $142.38.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.